Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford Bayer Healthcare Collaborative Research Alliance on Women's Health

AIMS

The University of Oxford and Bayer HealthCare have entered into a strategic research alliance in the area of gynaecological therapies. The multi-target collaboration focuses on endometriosis and uterine fibroids with the goal of discovering and developing innovative treatment options for these diseases. The alliance is for an initial period of up to five years.

“Clearly novel approaches are required to better understand these devastating diseases and develop novel therapeutic concepts to treat endometriosis and uterine fibroids. Oxford with its excellent translational approaches and departments can perfectly contribute to this challenging task.” Prof Udo Oppermann - Oxford’s Scientific Director in the alliance and Director of Laboratory Sciences at the Botnar Research Centre

Related research themes